Clinical trials
Phase 3 Angina Pectoris trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 2 |
| 2004 | 4 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 2 |
| 2019 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 22 |
| Unknown status | 4 |
| Terminated | 3 |
| Enrolling by invitation | 1 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Gilead Sciences | 3 |
| National Heart, Lung, and Blood Institute (NHLBI) | 3 |
| Cardium Therapeutics | 2 |
| Organon and Co | 2 |
| Pfizer | 2 |
| Tasly Pharmaceuticals, Inc. | 2 |
| Amarin Pharma Inc. | 1 |
| Angionetics Inc. | 1 |
| Bayer | 1 |
| Brigham and Women's Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Angina Pectoris | 32 |
| Myocardial Ischemia | 15 |
| Coronary Artery Disease | 14 |
| Heart Diseases | 8 |
| Cardiovascular Diseases | 7 |
| Coronary Disease | 6 |
| Myocardial Infarction | 5 |
| Acute Coronary Syndrome | 4 |
| Chest Pain | 4 |
| Ischemia | 4 |
Trials
Showing 51 to 32 of 32. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.